Medicali's S.R.L.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The department focuses on cardiovascular disease research, exploring conditions such as acute myocardial infarction, heart failure, hypertension, atherosclerotic disease and related kidney complications. Trials aim to test innovative therapies that lower major adverse cardiovascular events, improve heart function, and manage blood pressure and lipid levels.
- Novel LDL‑C lowering agents to prevent heart attacks and strokes
- Combination therapies for heart failure with preserved or reduced ejection fraction
- Self‑administered treatments for suspected acute myocardial infarction
- Lipoprotein(a) reduction strategies to lower cardiovascular risk
- Renal outcome‑focused cardiovascular outcome trials
With 14 active studies and a team of 10 investigators, Medicali's S.R.L. in Timisoara provides a multidisciplinary environment for advancing cardiovascular care.
Musculoskeletal Diseases
Research in the musculoskeletal field concentrates on osteoarthritis of the knee and the associated moderate to severe pain. The primary goal is to evaluate safety, tolerability and pain‑relief efficacy of new intra‑articular agents, aiming to improve patient mobility and quality of life.
- Intra‑articular therapies for knee osteoarthritis
- Pain reduction outcomes using novel injectable compounds
- Long‑term safety monitoring of emerging musculoskeletal treatments
- Quality‑of‑life assessments in patients with joint pain
- Integration of imaging biomarkers for treatment response
The site’s focused trials complement its cardiovascular program, offering comprehensive care for patients with joint disorders.
Nutritional and Metabolic Diseases
The metabolic research portfolio addresses obesity, type 2 diabetes, and disorders of lipid metabolism such as hypertriglyceridemia. Studies test new agents that promote weight loss, lower triglycerides, and reduce cardiovascular risk in high‑risk metabolic populations.
- Weight‑loss therapies targeting obesity and overweight
- RNA‑based treatments for severe hypertriglyceridemia
- Lipoprotein(a) lowering approaches for metabolic risk reduction
- Combination of SGLT2‑inhibitors with novel agents in type 2 diabetes
- Cardiovascular outcome trials in patients with metabolic disease
These investigations, conducted alongside the cardiovascular and musculoskeletal programs, reflect the site’s commitment to tackling interrelated chronic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medicali's S.R.L.
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 3 | Unknown | 2024-10-18 | 2025-10-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.